Résultats liés au cancer de la prostate : Un registre international pour améliorer les résultats chez les hommes atteints d’un cancer avancé de la prostate (IRONMAN – International Registry to Improve Outcomes in Men With Advanced Prostate Cancer)
IRONMAN
NCT03151629
 Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Amal Nadiri
514-890-8000 poste 26074
|
Le rôle de la stratification thérapeutique de la radiothérapie corporelle stéréotaxique avec le darolutamide dans la prise en charge du cancer de la prostate oligoprogressif résistant à la castration : essai pilote de phase II
PCS X
NCT04070209
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Mom Phat
514-890-8000 poste 11171
|
(EN) Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer
ANCHOR-Prostate
NCT05457699
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Mom Phat
514-890-8000 poste 11171
|
(EN) Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging
PROSTEP-002
NCT04655365
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Amal Nadiri
514-890-8000 poste 26074
|
(EN) An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)
PSMA-DC
NCT05939414
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Mom Phat
514-890-8000 poste 11171
|
(EN) A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
PAnTHA
NCT06217822
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Amal Nadiri
514-890-8000 poste 26074
|
(EN) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation
PREDICT-RT*
NCT04513717
Actif en recrutement
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
 HOPITAL FLEURIMONT
|
|
Patricia Roy
819-346-1110 poste 14082
|
(EN) A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
ARASTEP
NCT05794906
Actif en recrutement
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
|
Estel Duquet Deblois
418-835-7121 poste 11790
|
(EN) Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
PCS-XI
NCT05820633
Actif en recrutement
|
CISSS DE L'OUTAOUAIS
HOPITAL DE GATINEAU
|
|
Céline Roy
819-966-6100 poste 3669
|
(EN) A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
ARASTEP
NCT05794906
Actif en recrutement
|
CISSS DE L'OUTAOUAIS
HOPITAL DE GATINEAU
|
|
Céline Roy
819-966-6100 poste 3669
|
Groupe d'étude en oncologie du Québec